Chartwell Investment Partners’s AstraZeneca AZN Stock Holding History

Chartwell Investment Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-69,318	Closed	-$3.79M	–	409
2016 Q4	$3.79M	Hold	69,318	–	–	0.13%	232
2016 Q3	$4.56M	Buy	69,318 +4,755	+7%	+$311K	0.08%	266
2016 Q2	$3.9M	Buy	64,563 +63	+0.1%	+$3.66K	0.07%	261
2016 Q1	$3.63M	Sell	64,500 -53,233	-45%	-$3.2M	0.07%	235
2015 Q4	$7.99M	Sell	117,733 -1,472	-1%	-$96.5K	0.16%	172
2015 Q3	$7.59M	Hold	119,205	–	–	0.16%	183
2015 Q2	$7.59M	Sell	119,205 -2,815	-2%	-$193K	0.15%	202
2015 Q1	$8.35M	Buy	122,020 +107,020	+713%	+$7.44M	0.16%	203
2014 Q4	$1.06M	Hold	15,000	–	–	0.02%	327
2014 Q3	$1.07M	Hold	15,000	–	–	0.02%	315
2014 Q2	$1.11M	Sell	15,000 -18,200	-55%	-$1.32M	0.02%	312
2014 Q1	$2.15M	Hold	33,200	–	–	0.04%	289
2013 Q4	$1.97M	Hold	33,200	–	–	0.04%	296
2013 Q3	$1.72M	Buy	+33,200	New	+$1.67M	0.04%	311

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Chartwell Investment Partners's AZN Position: Q1 2017 in Review

Chartwell Investment Partners sold out of AstraZeneca (AZN) in Q1 2017, closing a stake of 69,318 shares — an estimated $3.79M sold.

Chartwell Investment Partners first reported a position in AZN in Q3 2013 and held it in 14 quarters. The position peaked at $8.35M in Q1 2015. 461 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

Chartwell Investment Partners reported no remaining AstraZeneca position as of Q1 2017 after selling out during the quarter.
Chartwell Investment Partners sold 69,318 AstraZeneca shares in Q1 2017, an estimated $3.79M.
Chartwell Investment Partners first reported a position in AstraZeneca in Q3 2013 and held it in 14 quarters.
Chartwell Investment Partners's AstraZeneca position peaked at $8.35M in Q1 2015.
461 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on Chartwell Investment Partners's 13F filing for Q1 2017, filed 12 May 2017.